Cheng Daye, Hao Yiwen, Zhou Wenling, Ma Yiran
Department of Transfusion, The First Hospital of China Medical University, North Nanjing Street, No. 155, Shenyang, Liaoning 110001, China.
Biomed Res Int. 2014;2014:290687. doi: 10.1155/2014/290687. Epub 2014 Jun 5.
Recent studies have suggested that IL-18 -607C/A and -137G/C polymorphisms may be associated with the risk of allergic disease; however, individually published results are inconclusive. Therefore, we performed a meta-analysis to clarify whether IL-18 -607C/A and -137G/C polymorphisms were associated with the risk of allergic disease. A total of 21 studies including 5,331 cases and 9,658 controls were involved in this meta-analysis. In the overall analysis and the subgroup analysis according to ethnicity, we did not find significant association between IL-18 -607C/A or -137G/C polymorphism and the risk of allergic disease (all P > 0.05). However, in a stratified analysis by type of allergic disease, our results indicated that IL-18 -607C/A polymorphism was associated with a significantly decreased risk of allergic asthma in heterozygous comparison and IL-18 -137G/C was associated with a significantly decreased risk of allergic dermatitis in recessive model and homozygous comparison. In the stratified analysis by source of control, IL-18-607C/A showed significantly reduced risk in population-based subgroup, and for IL-18 -137G/C only significantly decreased risk was found in the hospital-based subgroup. Our meta-analysis suggests that IL-18 -607C/A and -137G/C polymorphisms may be protective factors for the risk of allergic asthma and allergic dermatitis, respectively.
近期研究表明,白细胞介素-18(IL-18)-607C/A和-137G/C基因多态性可能与过敏性疾病风险相关;然而,单独发表的研究结果尚无定论。因此,我们进行了一项荟萃分析,以阐明IL-18 -607C/A和-137G/C基因多态性是否与过敏性疾病风险相关。本荟萃分析共纳入21项研究,包括5331例病例和9658例对照。在总体分析以及按种族进行的亚组分析中,我们未发现IL-18 -607C/A或-137G/C基因多态性与过敏性疾病风险之间存在显著关联(所有P>0.05)。然而,在按过敏性疾病类型进行的分层分析中,我们的结果表明,在杂合子比较中,IL-18 -607C/A基因多态性与过敏性哮喘风险显著降低相关,在隐性模型和纯合子比较中,IL-18 -137G/C与过敏性皮炎风险显著降低相关。在按对照来源进行的分层分析中,IL-18-607C/A在基于人群的亚组中显示风险显著降低,而对于IL-18 -137G/C,仅在基于医院的亚组中发现风险显著降低。我们的荟萃分析表明,IL-18 -607C/A和-137G/C基因多态性可能分别是过敏性哮喘和过敏性皮炎风险的保护因素。